A multiplex assay for detecting Genetic variations in cyp2c9, vkorc1, and GGCX involved in warfarin metabolism

Clinical Chemistry

Volumn 55, Issue 4, 2009, Pages 823-826

  Rai, Alex J ^a   Udar, Nitin ^b   Saad, Rana ^c   Fleisher, Martin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BECKMAN COULTER INC   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450 2C9; GAMMA GLUTAMYL CARBOXYLASE; GENOMIC DNA; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN; CYP2C9 PROTEIN, HUMAN; GLUTAMYL CARBOXYLASE; LIGASE; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; BLOOD SAMPLING; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; DRUG METABOLISM; GENE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PROCEDURES; GENETICS; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CARBON-CARBON LIGASES; GENETIC TECHNIQUES; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; WARFARIN;

EID: 64149123779     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.118497     Document Type: Article

References (9)

1. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007;7:99-111.
2. El Rouby S, Mestres CA, LaDuca FM, Zucker ML. Racial and ethnic differences in warfarin response. J Heart Valve Dis 2004;13:15-21.
3. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol 2006;13:357-61.
4. US Food and Drug Administration. Critical Path Initiative: warfarin dosing. http://69.20.19.211/oc/initiatives/criticalpath/warfarin.html (Accessed Febru- ary 2009).
5. US Food and Drug Administration. New labeling in- formation for warfarin (marketed as Coumadin). http://www.fda.gov/cder/drug/infopage/warfarin/(Accessed February 2009).
6. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vita- min K epoxide reductase complex genes on war- farin dose requirement. Thromb Haemost 2006;95: 782-7.
7. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-70.
8. Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 2007;5:2227-34.
9. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 GA) and CYP2C9 genotypes. Clin Chem 2007;53:1199-205.